
## Eleni Timotheadou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8400019/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Research and Treatment, 2012, 132, 609-619.	1.1	48
2	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget, 2016, 7, 32731-32753.	0.8	30
3	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. PLoS ONE, 2015, 10, e0140293.	1.1	29
4	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. Breast, 2014, 23, 234-243.	0.9	26
5	Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer, 2014, 14, 515.	1.1	26
6	The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer. BMC Neurology, 2016, 16, 190.	0.8	21
7	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. Translational Oncology, 2017, 10, 589-598.	1.7	17
8	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. Journal of Translational Medicine, 2017, 15, 30.	1.8	14
9	Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast Cancer. Cancer Genomics and Proteomics, 2019, 16, 195-206.	1.0	13
10	Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Research, 2007, 27, 4481-9.	0.5	12
11	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. Clinical Breast Cancer, 2018, 18, 53-62.e3.	1.1	8
12	Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental. Anticancer Research, 2020, 40, 305-313.	0.5	8
13	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. Anticancer Research, 2016, 36, 2365-78.	0.5	6
14	Real-World Data on Thromboprophylaxis in Active Cancer Patients: Where Are We? Are We Getting There?. Cancers, 2020, 12, 1907.	1.7	5
15	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. PLoS ONE, 2016, 11, e0164013.	1.1	4
16	Prophylaxis of cancer‑associated venous thromboembolism with low‑molecular‑weight heparin‑tinzaparin: Real world evidence. Oncology Letters, 2022, 23, 115.	0.8	4
17	A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients' Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece. Cancers, 2022, 14, 1879.	1.7	3
18	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). Current Oncology, 2021, 28, 5266-5277.	0.9	1

#	Article	IF	CITATIONS
19	Hereditary Syndromes and Gynaecological Cancer. Advances in Medical Diagnosis, Treatment, and Care, 2021, , 22-30.	0.1	о